Email this article The hand-foot syndrome in oncological patients receiving chemotherapy
- Authors: Orlova E.V.1, Belousova T.A1, Grabovskaya O.V1, Sevidova L.Y.1, Bagirova A.A1
-
Affiliations:
- I.M. Setchenov First Moscow State Medical University
- Issue: Vol 18, No 5 (2015)
- Pages: 21-25
- Section: Articles
- URL: https://journals.rcsi.science/1560-9588/article/view/36974
- DOI: https://doi.org/10.17816/dv36974
- ID: 36974
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina V. Orlova
I.M. Setchenov First Moscow State Medical University
Email: kolip7@mail.ru
assistent 119991, Moscow, Russia
T. A Belousova
I.M. Setchenov First Moscow State Medical UniversityКафедра кожных и венерических болезней им. В.А. Рахманова лечебного факультета; кандидат мед. наук, доцент 119991, Moscow, Russia
O. V Grabovskaya
I.M. Setchenov First Moscow State Medical UniversityКафедра кожных и венерических болезней им. В.А. Рахманова лечебного факультета; кандидат мед. наук, доцент 119991, Moscow, Russia
L. Yu Sevidova
I.M. Setchenov First Moscow State Medical UniversityКафедра кожных и венерических болезней им. В.А. Рахманова лечебного факультета; кандидат мед. наук, ассистент 119991, Moscow, Russia
A. A Bagirova
I.M. Setchenov First Moscow State Medical University
Email: ayna_bagirova@mail.ru
Кафедра кожных и венерических болезней им. В.А. Рахманова лечебного факультета; врач-ординатор 119991, Moscow, Russia
References
- Beveridge R.A., Kales A.N., Binder R.A., Miller J.A., Virts S.G. Pyridoxine (B6) and amelioration of hand/foot syndrome. Proc. Am. Soc. Clin. Oncol. 1990; 9 (Suppl): 102a.
- Yarbro C.H., Frogge M.H., Goodman M. Cancer symptom management. Sudbury: Jones and Bartlett Publishers; 2004.
- Gabizon A., Goldenhersh M.A., Hubert A., Ingber A., Lotem M., Peretz T., Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch. Dermatol. 2000; 136(12): 1475-80.
- Lorusso D., Di Stefano A., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicin-related palmarplantar erythrodysesthesia («hand-foot»-syndrome). Ann. Oncol. 2007; 18(7): 1159-64.
- Martschick A., Sehouli J., Patzelt A., Richter H., Jacobi U., Oskay-Ozcelik G., et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res. 2009; 29(6): 2307-13.
- Болотина Л.В., Горбунова В.А., Кононенко И.Б., Моисеенко В.М., Орлова Е.В. и др. В сб.: Практические рекомендации по лечению злокачественных опухолей и практические рекомендации по поддерживающей терапии в онкологии. М.: RUSSCO; 2014: 371-4.
- Gressett S.M., Stanford B.L., Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J. Oncol. Pharm. Pract. 2006; 12(3): 131-41.
- Lipworth A.D., Robert C., Zhu A.X. Hand-foot syndrome (handfoot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009; 77(5): 257-71. doi: 10.1159/000258880.
- Kara I.O., Sahin B., Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast. 2006; 15(3): 414-24.
- Mangili G., Petrone M., Gentile C., De Marzi P., Vigano R., Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: The role of regional cooling. Gynecol. Oncol. 2008; 108(2): 332-35.
